Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

被引:64
作者
Papadaki, T
Stamatopoulos, K
Stavroyianni, N
Paterakis, G
Phisphis, M
Stefanoudaki-Sofianatou, K
机构
[1] Evangelismos Med Ctr, Hemopathol Unit, Athens, Greece
[2] Univ Athens, Sch Med, Dept Med 1, GR-11527 Athens, Greece
[3] G Gennimatas Hosp, Immunol Lab, Athens, Greece
[4] Amalia Fleming Hosp, Dept Hematol, Athens, Greece
关键词
lymphoma; Rituximab; neutropenia; T-LGL;
D O I
10.1016/S0145-2126(01)00183-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report two cases with B cell malignancies (case #1: refractory mantle cell lymphoma; case #2: lymphocyte predominant Hodgkin's disease (LPHD)) who developed neutropenia post-Rituximab therapy in a setting of significant infiltration of the peripheral blood (PB) and bone marrow (BM) by T cells with an immunophenotype of large granular lymphocytes. Possible pathogenetic mechanisms are discussed. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:597 / 600
页数:4
相关论文
共 8 条
[1]  
Coakley G, 2000, ARTHRITIS RHEUM, V43, P834, DOI 10.1002/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO
[2]  
2-H
[3]  
Douglas VK, 1999, AM J CLIN PATHOL, V112, P844
[4]   Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma [J].
Flinn, IW ;
O'Donnell, PV ;
Goodrich, A ;
Vogelsang, G ;
Abrams, R ;
Noga, S ;
Marcellus, D ;
Borowitz, M ;
Jones, R ;
Ambinder, RF .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (06) :628-632
[5]   Rituximab:: An insider's historical perspective [J].
Grillo-López, AJ .
SEMINARS IN ONCOLOGY, 2000, 27 (06) :9-16
[6]  
Liu JH, 2000, BLOOD, V95, P3219
[7]  
Semenzato G, 1997, BLOOD, V89, P256
[8]   Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma [J].
Vose, JM ;
Link, BK ;
Grossbard, ML ;
Czuczman, M ;
Grillo-Lopez, A ;
Gilman, P ;
Lowe, A ;
Kunkel, LA ;
Fisher, RI .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :389-397